We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Mega-Randomized Clinical Trials for Blockbuster Drugs—Reply

John P. A. Ioannidis, MD, DSc
JAMA. 2013;309(16):1682-1683. doi:10.1001/jama.2013.2742.
Text Size: A A A
Published online


In Reply: Mega-trials for blockbusters are readily feasible. There would be no cost for the government or health care system. Drug production cost to industry (as opposed to sales cost) is negligible. The proposed mandate could easily stipulate that blockbuster manufacturers donate drugs and placebos for such trials. Total cost to the industry would be approximately 1% of their cumulative sales for the product.

Assume a reward mechanism in which a positive result in a trial that takes T years generates a 1-year patent extension. Expected sales with and without the trial are M’ = TS0 + (t + 1)SpC + tSn(1 − C) and M = (T + t)S0, respectively, in which t is the number of remaining years in the original patent after the trial finishes, C is the probability to get a positive result, and Sp, Sn, S0 are average annual sales, if the result is positive, negative, or no trial is performed, respectively. The excess expected sales with the trial (M’ − M) easily exceed the 1% cost, unless both C is low (it is unlikely to get positive results) and Sn is much less than S0 (negative results are devastating for the drug market).


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




April 24, 2013
David C. Landy, PhD, MPH; Eric M. Hecht, MD, MSPH
JAMA. 2013;309(16):1682-1683. doi:10.1001/jama.2013.2736.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...